Applied DNA SciencesAPDN
About: Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
Employees: 48
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
33% more funds holding
Funds holding: 21 [Q3] → 28 (+7) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
5.21% less ownership
Funds ownership: 7.38% [Q3] → 2.17% (-5.21%) [Q4]
86% less capital invested
Capital invested by funds: $1.64M [Q3] → $230K (-$1.41M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for APDN.
Financial journalist opinion
Based on 5 articles about APDN published over the past 30 days









